z-logo
open-access-imgOpen Access
Mitochondria‐specific nanocatalysts for chemotherapy‐augmented sequential chemoreactive tumor therapy
Author(s) -
Huang Hui,
Dong Caihong,
Chang Meiqi,
Ding Li,
Chen Liang,
Feng Wei,
Chen Yu
Publication year - 2021
Publication title -
exploration
Language(s) - English
Resource type - Journals
eISSN - 2766-2098
pISSN - 2766-8509
DOI - 10.1002/exp.20210149
Subject(s) - prodrug , reactive oxygen species , mitochondrion , chemistry , cancer research , cisplatin , oxidative stress , chemotherapy , pharmacology , biochemistry , biology , genetics
Endogenic tumor chemodynamic therapy (CDT) is emerging as a tumor‐therapeutic strategy featuring in situ treatments with high efficiency and specificity based on the Fenton reaction principle. Considering the limitation of monotherapy and relatively insufficient intracellular level of endogenous hydrogen peroxide (H 2 O 2 ) in tumor tissues, a mitochondria‐specific nanocatalyst composed of cisplatin prodrug and gallic acid‐ferrous (GA‐Fe(II)) nanocomposites is successfully fabricated to fulfill chemotherapy‐augmented sequential chemoreactive tumor therapy. The bioactive cisplatin elevates the level of endogenous H 2 O 2 through the activation of nicotinamide adenine dinucleotide phosphate oxidase (NOX)‐related cascaded reactions, and the GA‐Fe(II) nanocomposites possessing sustainable Fenton catalytic activity subsequently catalyzes H 2 O 2 into highly reactive and toxic hydroxyl radicals to substantially inhibit tumor progression. Especially, this mitochondria‐specific nanocatalyst amplifies oxidative stress, stimulates mitochondrial dysfunction, downregulates AKT/mTOR signaling and finally induces cell autophagic death. Both in vitro and in vivo measurements verify that the chemotherapy‐augmented sequential chemoreactive nanotherapy based on the mitochondria‐specific nanocatalyst implements excellent anticancer efficiency and avoids undesired side effects. This work reveals the enormous potential of chemotherapy‐augmented CDT for combating tumors.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here